SCHEMBL442921

SCHEMBL442921

CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)OC(=O)C(O)CCCCCCCCCCCCCCCC

nearest known ligand 0.57

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.57
FFAR1 O14842 2/20 0.57
ZDHHC7 Q9NXF8 1/20 0.46
FAAH O00519 1/20 0.44
FFAR4 Q5NUL3 1/20 0.43
ABCB1 P08183 1/20 0.43
NAAA Q02083 1/20 0.42
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28359892 1.00 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4
SCHEMBL5692265 1.00 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4
SCHEMBL12802816 1.00 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4
Pentane SCHEMBL8332560 0.98 GPR84 (0.55) GPR84FFAR1ZDHHC7FAAHFFAR4
SCHEMBL2580544 0.92 GPR84 (0.45) GPR84FFAR1ZDHHC7NAAA
SCHEMBL27844491 0.86 GPR84 (0.44) GPR84FFAR1ZDHHC7NAAA
SCHEMBL5810994 0.85 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4
SCHEMBL4981858 0.85 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4
SCHEMBL30778412 0.85 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4
SCHEMBL3312860 0.85 GPR84 (0.57) GPR84FFAR1ZDHHC7FAAHFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4604746-B1 ORAL PRODUCT COMPRISING THEOBROMINE CONTRAF NICOTEX TOBACCO GMBH (DE) 2026-05-13 EP claimed
EP-4523549-A1 ORAL PRODUCT COMPRISING THEOBROMINE Contraf-Nicotex-Tobacco GmbH (DE) 2025-03-19 EP claimed
US-20250000770-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING KETYL/ACETYL OF GLYCERIN COMPOUND L'OREAL (FR) 2025-01-02 US claimed
US-20210186887-A1 MOISTURE RESISTANT PROBIOTIC GRANULE AND METHODS OF PRODUCING THE SAME POLYCAPS HOLDINGS LTD (IL) 2021-06-24 US claimed
EP-2863996-B1 LIQUID COSMETIC COMPOSITION COMPRISING AN OIL, HYDROPHOBIC SILICA AEROGEL PARTICLES AND A WAX WITH A MELTING POINT OF GREATER THAN 60°C OREAL (FR) 2021-03-24 EP claimed
EP-3781137-A1 MOISTURE RESISTANT PROBIOTIC GRANULE AND METHODS OF PRODUCING THE SAME Polycaps Holdings Ltd. (IL) 2021-02-24 EP claimed
US-20200405797-A1 TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME NANOSTRIPS, INC. (US) 2020-12-31 US claimed
US-20200093717-A1 EXFOLIATING AND HYDRATING MAKEUP REMOVING COMPOSITIONS L'OREAL (FR) 2020-03-26 US claimed
US-10576031-B1 Exfoliating and hydrating makeup removing compositions L'OREAL (FR) 2020-03-03 US claimed
US-10543175-B1 Film composition and methods for producing the same DEGAMA BERRIER LTD (KY) 2020-01-28 US claimed
EP-2549977-A2 LIPID NANOPARTICLE CAPSULES Lipotec, S.A. (ES) 2013-01-30 EP claimed
US-20130017239-A1 LIPID NANOPARTICLE CAPSULES LIPOTEC S.A. (ES) 2013-01-17 US claimed
WO-2012168882-A1 COMPOSITIONS AND METHODS FOR IMPROVING STABILITY AND EXTENDING SHELF LIFE OF SENSITIVE FOOD ADDITIVES AND FOOD PRODUCTS THEREOF SPAI Group Ltd. (US) 2012-12-13 WO claimed
WO-2011116963-A2 LIPID NANOPARTICLE CAPSULES LIPOTEC S.A. (ES) 2011-09-29 WO claimed
US-20090170876-A1 Novel Topical Formulations of Flucytosine CAMARGO PHARMACEUTICAL SERVICES, LLC (US) 2009-07-02 US claimed
US-20090142289-A1 COMPOSITION CONTAINING A HARD WAX AND A PASTY COMPOUND, AND PROCESS FOR THE CARE OR MAKING UP OF THE EYELASHES L'OREAL (FR) 2009-06-04 US claimed
US-20090068287-A1 Novel topical formulations of flucytosine and uses thereof CAMARGO PHARMACEUTICAL SERVICES LLC 2009-03-12 US claimed
US-20050053636-A1 Cosmetic and dermatological care oils containing waxes BEIERSDORF AG (DE) 2005-03-10 US claimed
EP-0680746-B1 Sunscreen composition SPIRIG PHARMA AG (CH) 2001-10-24 EP claimed
EP-0580620-B1 STABLE MULTIPLE EMULSIONS BEIERSDORF AG (DE) 2000-10-18 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093717-A1 EXFOLIATING AND HYDRATING MAKEUP REMOVING COMPOSITIONS DSG1, AQP3, AQP1 GPR84 3087/4885FFAR1 520/4885ZDHHC7 1022/4885
US-20250000770-A1 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING KETYL/ACETYL OF GLYCERIN COMPOUND GK, KAT8, KAT5 GPR84 661/4885FFAR1 768/4885ZDHHC7 580/4885
US-10543175-B1 Film composition and methods for producing the same LCAT, LCT, LIPA GPR84 1705/4885FFAR1 612/4885ZDHHC7 1284/4885
US-10576031-B1 Exfoliating and hydrating makeup removing compositions DSG1, AQP3, AQP1 GPR84 3087/4885FFAR1 520/4885ZDHHC7 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.